Dergiler / Balıkesir Sağlık Bilimleri Dergisi / 2025 / Volume: 14 Issue: 3

Majör Depresif Bozukluk Tanılı Hastalarda Çinko-Alfa-2-Glikoprotein Düzeyleri ve Obezite ile İlişkisi

Zinc Alpha-2-Glycoprotein Levels and Their Correlations with Obesity in Patients with Major Depressive Disorder

Esra Arslan(yüzyıl pendik hastanesi)0009-0009-6489-8327
Tuğçin Mutlu(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0007-3775-8340
Furkan Akbaş(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0004-0516-2583
Hayriye Baykan(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-3288-2269
Mehmet Orbay Soğucak(Balıkesir Üniversitesi Tıp Fakültesi)0009-0007-7815-0278
Mervan Uğur Yağcı(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0008-4132-0947
Meryem Gül(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0008-7683-6644
Özgür Baykan(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-8551-6900
Sayfa
—
Yayın Tarihi
2025-10-31
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgular: Kontrol grubunda ZAG düzeyleri medyan 69,0 (19–150) µg/ml, hasta grubunda ise 32,4 (0,5–150) µg/ml olarak bulunmuştur.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amaç: Majör depresif bozukluk (MDD), çeşitli psikolojik, fiziksel ve bilişsel semptomlarla seyreden en yaygın duygudurum bozukluğudur.
📊
Temel Bulgular & Veri:Çinko alfa-2-glikoprotein (ZAG), çeşitli dokularda bulunan ve vücut sıvılarına salgılanan 41–43 kDa ağırlığında bir glikoprotein olup, potansiyel bir biyobelirteç adayıdır.
💡
Sonuç & Katkı:Bulgular: Kontrol grubunda ZAG düzeyleri medyan 69,0 (19–150) µg/ml, hasta grubunda ise 32,4 (0,5–150) µg/ml olarak bulunmuştur.
🔬Tür:Laboratuvar & Saha Deneyi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:major depressive disorder · obesity · Body Mass Index

Özet

Amaç: Majör depresif bozukluk (MDD), çeşitli psikolojik, fiziksel ve bilişsel semptomlarla seyreden en yaygın duygudurum bozukluğudur. Tanısı büyük ölçüde yapılandırılmış klinik görüşmelere dayanan subjektif bir süreçtir. Yeni biyobelirteçlerin tanımlanması, tanısal doğruluğu artırabilir. Çinko alfa-2-glikoprotein (ZAG), çeşitli dokularda bulunan ve vücut sıvılarına salgılanan 41–43 kDa ağırlığında bir glikoprotein olup, potansiyel bir biyobelirteç adayıdır. Bu çalışma, ZAG’ın MDD’nin ayırıcı tanısındaki rolünü ve obezite ile olan ilişkisini değerlendirmeyi amaçlamaktadır. Gereç ve Yöntem: Çalışmaya Balıkesir Üniversitesi Psikiyatri Anabilim Dalı’ndan 44 MDD hastası ve 40 sağlıklı kontrol birey dahil edilmiştir. Serum ZAG düzeyleri ELISA kiti kullanılarak ölçülmüştür. Bulgular: Kontrol grubunda ZAG düzeyleri medyan 69,0 (19–150) µg/ml, hasta grubunda ise 32,4 (0,5–150) µg/ml olarak bulunmuştur. Gruplar arasındaki fark istatistiksel olarak anlamlı bulunmadı. ZAG düzeyleri ile beden kitle indeksi (BKİ) arasında anlamlı bir ilişki bulunmamıştır (P=0,063). ZAG düzeyi ile MDD arasında negatif yönde zayıf korelasyon gözlendi (P=0.012, rs =-0.272). Sonuç: MDD hastalarında ZAG düzeylerinin sağlıklı kontrollere göre daha düşük olduğu görülmüş ve bu durum depresyon şiddetiyle ilişkili olabileceği düşünülmüştür. ZAG’ın MDD için biyobelirteç olarak kullanılabilirliğini netleştirmek amacıyla ileri çalışmalara ihtiyaç vardır. Anahtar Kelimeler: Beden Kitle İndeksi, Majör Depresif Bozukluk, Obezite.

Abstract

Objective: Major depressive disorder (MDD) is the most prevalent mood disorder, presenting a range of psychological, physical, and cognitive symptoms. Diagnosis is a subjective process that predominantly relies on structured clinical interviews. The identification of novel biomarkers could improve diagnostic precision. Zinc alpha-2-glycoprotein (ZAG), a 41–43 kDa glycoprotein present in various tissues and secreted into body fluids, has emerged as a candidate biomarker. This study aims to evaluate the role of ZAG in the differential diagnosis of MDD and its association with obesity. Materials and Methods: The study included 44 patients with MDD and 40 healthy controls. Serum ZAG levels were measured using an ELISA kit. Results: Median ZAG levels were 69.0 (19–150) µg/ml in controls and 32.4 (0.5–150) µg/ml in MDD patients. The difference was not statistically significant. No significant correlation was found between ZAG levels and BMI (p=0.063). A weak negative correlation was observed between ZAG level and MDD (p=0.012, r=-0.272). Conclusion: ZAG levels were lower in MDD patients compared to healthy controls, potentially reflecting the severity of depressive symptoms. Further studies are required to clarify the utility of ZAG as a biomarker for MDD.

🔖

Bu Makaleye Atıf Yap

Arslan, E., Mutlu, T., Akbaş, F., Baykan, H., Soğucak, M. O., Yağcı, M. U., Gül, M., Baykan, Ö. (2025). Majör Depresif Bozukluk Tanılı Hastalarda Çinko-Alfa-2-Glikoprotein Düzeyleri ve Obezite ile İlişkisi. Balıkesir Sağlık Bilimleri Dergisi, Volume: 14 Issue: 3. https://doi.org/10.53424/balikesirsbd.1676846

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (38)

  1. Akdemir, A., Türkçapar, M. H., Orsel, S. D., Demirergi, N., Dag, I., & Ozbay, M. H. (2001). Reliability and validity of the turkish version of the hamilton depression rating scale. Comprehensive Psychiatry, 42(2), 161–165. https://doi.org/10.1053/comp.2001.19756
  2. Alberti, A., Araujo Coelho, D. R., Vieira, W. F., Moehlecke Iser, B., Lampert, R. M. F., Traebert, E., Silva, B. B. da, Oliveira, B. H. de, Leão, G. M., Souza, G. de, Dallacosta, F. M., Kades, G., Madeira, K., Chupel, M. U., Grossl, F. S., Souza, R., Hur Soares, B., Endrigo Ruppel da Rocha, R., da Silva Sipriano, E., … Agostinetto, L. (2024). Factors associated with the development of depression and the influence of obesity on depressive disorders: a narrative review.
  3. Biomedicines, 12(9), 1994. https://doi.org/10.3390/BIOMEDICINES12091994
  4. Anna, J., Elżbieta, Ś., Elżbieta M-I, Katarzyna G-J, Katarzyna B-D, Katarzyna Z. ZAG (ZincAlpha 2 Glycoprotein) serum levels in girls with anorexia nervosa. Journal of Clinical Medicine. 2023; 12(13):4245. https://doi.org/10.3390/jcm12134245
  5. Balaz, M.; Vician, M.; Janakova, Z.; Kurdiova, T.; Surova, M.; Imrich, R.; Majercikova, Z.; Penesova, A.; Vlcek, M.; Kiss, A.; et al. Subcutaneous adipose tissue zinc-α2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. Obesity 2014, 22, 1821–1829. https://doi.org/10.1002/oby.20764
  6. Banaszak, M., Górna, I., & Przysławski, J. (2021). Zinc and the innovative zinc-α2-glycoprotein adipokine play an important role in lipid metabolism: a critical review. Nutrients, 13(6), 2023. https://doi.org/10.3390/NU13062023
  7. Barraco, G. M., Luciano, R., & Manco, M. (2015). Zinc-α2-glycoprotein is associated with insulin resistance in children. Obesity, 23(1), 5–6. https://doi.org/10.1002/oby.20948
  8. Bouchara, A., Yi, D., Pastural, M., Granjon, S., Selag, J. C., Laville, M., Arkouche, W., Pelletier, S., Fouque, D., Soulage, C. O., & Koppe, L. (2018). Serum levels of the adipokine zinc-alpha2-glycoprotein (ZAG) predict mortality in hemodialysis patients. Kidney International, 94(5), 983–992. https://doi.org/10.1016/j.kint.2018.07.019
  9. Chan, G. C. K., Than, W. H., Kwan, B. C. H., & Szeto, C. C. (2022). Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients. Scientific Reports, 12, 9087. https://doi.org/10.1038/s41598-022-13149-6
  10. Choi, H., Mun, S., Joo, E. J., Lee, K. Y., Kang, H. G., & Lee, J. (2021). Serum proteomic analysis of major depressive disorder patients and their remission status: Novel biomarker set of zinc-alpha-2-glycoprotein and keratin type II cytoskeletal 1. International Journal of Biological Macromolecules, 183, 2001–2008. https://doi.org/10.1016/j.ijbiomac.2021.05.1720000
  11. Ferrari, A. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry, 9(2), 137–150. https://doi.org/10.1016/S2215-0366(21)00395-3
  12. Fleetwood, K. J., Guthrie, B., Jackson, C. A., Kelly, P. A. T., Mercer, S. W., Morales, D. R., Norrie, J. D., Smith, D. J., Sudlow, C., & Prigge, R. (2025). Depression and physical multimorbidity: A cohort study of physical health condition accrual in UK Biobank. PLOS Medicine, 22(2), e1004532. https://doi.org/10.1371/JOURNAL.PMED.1004532
  13. Fu, X., Wang, Y., Zhao, F., Cui, R., Xie, W., Liu, Q., & Yang, W. (2023). Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines. Aging, 15(12), 5917–5950. https://doi.org/10.18632/AGING.204847
  14. Fulton, S., Décarie-Spain, L., Fioramonti, X., Guiard, B., & Nakajima, S. (2022). The menace of obesity to depression and anxiety prevalence. Trends in Endocrinology and Metabolism: TEM, 33(1), 18–35. https://doi.org/10.1016/j.tem.2021.10.005
  15. Gebresenbet, E. A., Zegeye, S., & Biratu, T. D. (2025). Prevalence and associated factors of depression and posttraumatic stress disorder among trauma patients: multi-centered cross-sectional study. Frontiers in Psychiatry, 16, 1447232. https://doi.org/10.3389/FPSYT.2025.1447232
  16. Gong, F. Y., Zhang, S. J., Deng, J. Y., Zhu, H. J., Pan, H., Li, N. S., & Shi, Y. F. (2009). Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. International Journal of Obesity, 33(9), 1023–1030. https://doi.org/10.1038/ijo.2009.141
  17. Goodwin, G. M., & Stein, D. J. (2021). Generalised anxiety disorder and depression: contemporary treatment approaches. Advances in Therapy, 38(Suppl 2), 45–51. https://doi.org/10.1007/s12325-021-01859-8 Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32(1), 50–55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
  18. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23(1), 56–62. https://doi.org/10.1136/jnnp.23.1.56
  19. Hassamal S. (2023). Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Frontiers in Psychiatry, 14, 1130989. https://doi.org/10.3389/fpsyt.2023.1130989
  20. Hruby, A., & Hu, F. B. (2015). The Epidemiology of Obesity: A Big Picture. PharmacoEconomics, 33(7), 673. https://doi.org/10.1007/S40273-014-0243-X
  21. Huang, D., Mao, X., Peng, J., Cheng, M., Bai, T., Du, M., Huang, K., Liu, B., Yang, L., Huang, K., & Zhang, F. (2019). Role of adipokine zinc-α2-glycoprotein in coronary heart disease. American Journal of Physiology. Endocrinology and Metabolism, 317(6), E1055–E1062. https://doi.org/10.1152/ajpendo.00075.2019
  22. Kuehner, C. (2017). Why is depression more common among women than among men? The Lancet Psychiatry, 4(2), 146–158. https://doi.org/10.1016/S2215-0366(16)30263-2
  23. Lamers, F., Milaneschi, Y., Vinkers, C. H., Schoevers, R. A., Giltay, E. J., & Penninx, B. W. J. H. (2020). Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. Brain, Behavior, and Immunity, 88, 174–183. https://doi.org/10.1016/J.BBI.2020.04.002
  24. Lee, Y. P., Chang, C. H., Liu, H. H., Chen, C. Y., Chen, C. Y., Hsu, C. C., Chang, C. I., Lin, Y. T., Lee, C. S., & Tsai, J. S. (2016). Plasma zinc alpha2-glycoprotein levels correlate positively with frailty severity in female elders. Medicine, 95(35), e4753. https://doi.org/10.1097/MD.0000000000004753
  25. Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W., & Zitman, F. G. (2010). Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Archives of General Psychiatry, 67(3), 220–229. https://doi.org/10.1001/archgenpsychiatry.2010.2
  26. Mannan, M., Mamun, A., Doi, S., & Clavarino, A. (2016). Prospective associations between depression and obesity for adolescent males and females- a systematic review and meta-analysis of longitudinal studies. PloS one, 11(6), e0157240. https://doi.org/10.1371/journal.pone.0157240
  27. Mannelli, M., Gamberi, T., Magherini, F., & Fiaschi, T. (2020). The Adipokines in Cancer Cachexia. International Journal of Molecular Sciences, 21(14), 4860. https://doi.org/10.3390/ijms21144860
  28. Martínez-Montoro, J. I., Ocaña-Wilhelmi, L., Soler-Humanes, R., Motahari-Rad, H., González-Jiménez, A., Rivas-Becerra, J., Rodríguez-Muñoz, A., Moreno-Ruiz, F. J., Tomé, M., Rodríguez-Capitán, J., García-Fuentes, E., Tinahones, F. J., Garrido-Sánchez, L., & Murri, M. (2022). Evaluation of adipose tissue zinc-alpha 2-glycoprotein gene expression and its relationship with metabolic status and bariatric surgery outcomes in patients with class iii obesity. Biomedicines, 10(7), 1502. https://doi.org/10.3390/biomedicines10071502
  29. Pelletier, C. C., Koppe, L., Alix, P. M., Kalbacher, E., Croze, M. L., Hadj-Aissa, A., Fouque, D., Guebre-Egziabher, F., & Soulage, C. O. (2014). The relationship between renal function and plasma concentration of the cachectic factor zinc-alpha2-glycoprotein (ZAG) in adult patients with chronic kidney disease. PloS One, 9(7), e103475. https://doi.org/10.1371/journal.pone.0103475
  30. Penninx, B. W. J. H., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013). Understanding the somatic consequences of depression: Biological mechanisms and the role of depression symptom profile. BMC Medicine, 11(1). https://doi.org/10.1186/1741-7015-11-129,
  31. Qiu, W., Cai, X., Zheng, C., Qiu, S., Ke, H., & Huang, Y. (2021). Update on the Relationship Between Depression and Neuroendocrine Metabolism. Frontiers in Neuroscience, 15, 728810. https://doi.org/10.3389/FNINS.2021.728810/XML
  32. Selva, D.M.; Lecube, A.; Hernandez, C.; Baena, J.A.; Fort, J.M.; Simo, R. (2009). Lower zinc-α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insülin resistance. The Journal of Clinical Endocrinology & Metabolism. 94, 4499–4507. https://doi.org/10.1210/jc.2009-0758
  33. Stetler, C., & Miller, G. E. (2011). Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. Psychosomatic Medicine, 73(2), 114–126. https://doi.org/10.1097/PSY.0B013E31820AD12B
  34. Tedeschi, S., Pilotti, E., Parenti, E., Vicini, V., Coghi, P., Montanari, A., Regolisti, G., Fiaccadori, E., & Cabassi, A. (2012). Serum adipokine zinc α2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metabolism: Clinical and Experimental, 61(1), 37–42. https://doi.org/10.1016/j.metabol.2011.05.011
  35. Yazici, M. & Demir, Basaran & Tanriverdi Taskintuna, Nilgun & Karaağaoğlu, Efe & Yolaç, P. (1998). Hamilton Anxiety Rating Scale: Interrater reliability and validity study. Türk Psikiyatri Dergisi. 9. 114-117.
  36. Yeung, D. C., Lam, K. S., Wang, Y., Tso, A. W., & Xu, A. (2009). Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. The Journal of Clinical Endocrinology and Metabolism, 94(7), 2531–2536. https://doi.org/10.1210/jc.2009-0058
  37. Gong, F. Y., Zhang, S. J., Deng, J. Y., Zhu, H. J., Pan, H., Li, N. S., & Shi, Y. F. (2009). Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. International Journal of Obesity, 33(9), 1023–1030. https://doi.org/10.1038/ijo.2009.141
  38. Yazici, M. & Demir, Basaran & Tanriverdi Taskintuna, Nilgun & Karaağaoğlu, Efe & Yolaç, P. (1998). Hamilton Anxiety Rating Scale: Interrater reliability and validity study. Türk Psikiyatri Dergisi. 9. 114-117.